{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:22:29Z","timestamp":1785349349594,"version":"3.55.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson\u2019s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.<\/jats:p>","DOI":"10.1186\/s13195-022-01103-7","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T06:02:22Z","timestamp":1668146542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia\u2014an international Delphi consensus"],"prefix":"10.1186","volume":"14","author":[{"given":"John T.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Chouliaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RENEWAL Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Boeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Flicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald G.","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kohlhaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W.","family":"Lemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iracema","family":"Leroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Londos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Leverenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McKeith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Oakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svennigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona S.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H.","family":"Williams-Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Yarnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44:673\u201383.","journal-title":"Psychol Med"},{"key":"1103_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","volume":"10","author":"JPM Kane","year":"2018","unstructured":"Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor J-P, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10:19.","journal-title":"Alzheimers Res Ther"},{"key":"1103_CR3","first-page":"1455","volume":"66","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;66:1455.","journal-title":"Neurology"},{"key":"1103_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-018-1135-2","volume":"16","author":"Y-T Wu","year":"2018","unstructured":"Wu Y-T, Clare L, Hindle JV, Nelis SM, Martyr A, Matthews FE, et al. Dementia subtype and living well: results from the Improving the experience of Dementia and Enhancing Active Life (IDEAL) study. BMC Med. 2018;16:140.","journal-title":"BMC Med"},{"key":"1103_CR5","doi-asserted-by":"publisher","first-page":"e017504","DOI":"10.1136\/bmjopen-2017-017504","volume":"7","author":"A Price","year":"2017","unstructured":"Price A, Farooq R, Yuan J-M, Menon VB, Cardinal RN, O\u2019Brien JT. Mortality in dementia with Lewy bodies compared with Alzheimer\u2019s dementia: a retrospective naturalistic cohort study. BMJ Open. 2017;7:e017504.","journal-title":"BMJ Open"},{"key":"1103_CR6","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/brain\/awy265","volume":"141","author":"A Surendranathan","year":"2018","unstructured":"Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain. 2018;141:3415\u201327.","journal-title":"Brain"},{"key":"1103_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2017-317134","volume":"89","author":"E King","year":"2018","unstructured":"King E, O\u2019Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, et al. Peripheral inflammation in prodromal Alzheimer\u2019s and Lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89:339\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1103_CR8","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/brain\/awaa088","volume":"143","author":"M Malpetti","year":"2020","unstructured":"Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer\u2019s disease. Brain. 2020;143:1588\u2013602.","journal-title":"Brain"},{"key":"1103_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"J-P Taylor","year":"2020","unstructured":"Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19:157\u201369.","journal-title":"Lancet Neurol"},{"key":"1103_CR10","volume-title":"A double-blind, placebo-controlled 16-week study of the cognitive effects of oral p38 alpha kinase inhibitor neflamapimod in dementia with lewy bodies (DLB)","author":"EIP Pharma Inc","year":"2021","unstructured":"EIP Pharma Inc. A double-blind, placebo-controlled 16-week study of the cognitive effects of oral p38 alpha kinase inhibitor neflamapimod in dementia with lewy bodies (DLB): clinicaltrials.gov; 2021. Report no.: NCT04001517. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04001517."},{"key":"1103_CR11","doi-asserted-by":"publisher","first-page":"E5485","DOI":"10.3390\/ijms21155485","volume":"21","author":"UA Germann","year":"2020","unstructured":"Germann UA, Alam JJ. P38\u03b1 MAPK signaling-a robust therapeutic target for Rab5-mediated neurodegenerative disease. Int J Mol Sci. 2020;21:E5485.","journal-title":"Int J Mol Sci"},{"key":"1103_CR12","doi-asserted-by":"publisher","first-page":"172784","DOI":"10.1016\/j.ejphar.2019.172784","volume":"866","author":"M Antoszczak","year":"2020","unstructured":"Antoszczak M, Markowska A, Markowska J, Huczy\u0144ski A. Old wine in new bottles: drug repurposing in oncology. Eur J Pharmacol. 2020;866:172784.","journal-title":"Eur J Pharmacol"},{"key":"1103_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard C, Aarsland D, Cummings J, O\u2019Brien J, Mills R, Molinuevo JL, et al. Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol. 2020;16:661\u201373.","journal-title":"Nat Rev Neurol"},{"key":"1103_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"J Langedijk","year":"2015","unstructured":"Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens M-HDB. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20:1027\u201334.","journal-title":"Drug Discov Today"},{"key":"1103_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug repositioning for Alzheimer\u2019s disease. Nat Rev Drug Discov. 2012;11:833\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"1103_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4081\/mrm.2020.511","volume":"15","author":"A Kantar","year":"2020","unstructured":"Kantar A, Klimek L, Cazan D, Sperl A, Sent U, Mesquita M. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip Respir Med. 2020;15:511.","journal-title":"Multidiscip Respir Med"},{"key":"1103_CR17","doi-asserted-by":"publisher","first-page":"173446","DOI":"10.1016\/j.ejphar.2020.173446","volume":"884","author":"A Bouscary","year":"2020","unstructured":"Bouscary A, Quessada C, Ren\u00e9 F, Spedding M, Henriques A, Ngo S, et al. Drug repositioning in neurodegeneration: an overview of the use of ambroxol in neurodegenerative diseases. Eur J Pharmacol. 2020;884:173446.","journal-title":"Eur J Pharmacol"},{"key":"1103_CR18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","volume":"8","author":"J Magalhaes","year":"2018","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. Nature Publishing Group. 2018;8:1385.","journal-title":"Sci Rep"},{"key":"1103_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11910-017-0778-2","volume":"17","author":"L Velayudhan","year":"2017","unstructured":"Velayudhan L, Ffytche D, Ballard C, Aarsland D. New therapeutic strategies for Lewy body dementias. Curr Neurol Neurosci Rep. 2017;17:68.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1103_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. JAMA Neurol. 2020;77:427\u201334.","journal-title":"JAMA Neurol"},{"key":"1103_CR21","doi-asserted-by":"publisher","first-page":"e21967","DOI":"10.1002\/syn.21967","volume":"71","author":"A Migdalska-Richards","year":"2017","unstructured":"Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. 2017;71:e21967.","journal-title":"Synapse"},{"key":"1103_CR22","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S, Burbulla LF, et al. Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons. J Neurosci. 2016;36:7693\u2013706.","journal-title":"J Neurosci"},{"key":"1103_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00210-019-01737-9","volume":"393","author":"A Mishra","year":"2020","unstructured":"Mishra A, Krishnamurthy S. Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson\u2019s disease. Naunyn Schmiedeberg's Arch Pharmacol. 2020;393:429\u201344.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"1103_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.bcp.2018.07.028","volume":"155","author":"A Mishra","year":"2018","unstructured":"Mishra A, Chandravanshi LP, Trigun SK, Krishnamurthy S. Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson\u2019s disease symptoms. Biochem Pharmacol. 2018;155:479\u201393.","journal-title":"Biochem Pharmacol"},{"key":"1103_CR25","doi-asserted-by":"publisher","first-page":"104620","DOI":"10.1016\/j.nbd.2019.104620","volume":"134","author":"S-Y Yang","year":"2020","unstructured":"Yang S-Y, Gegg M, Chau D, Schapira A. Glucocerebrosidase activity, cathepsin D and monomeric \u03b1-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. Neurobiol Dis. 2020;134:104620.","journal-title":"Neurobiol Dis"},{"key":"1103_CR26","doi-asserted-by":"publisher","first-page":"31380","DOI":"10.1038\/srep31380","volume":"6","author":"A Sanchez-Martinez","year":"2016","unstructured":"Sanchez-Martinez A, Beavan M, Gegg ME, Chau K-Y, Whitworth AJ, Schapira AHV. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci Rep. 2016;6:31380.","journal-title":"Sci Rep"},{"key":"1103_CR27","first-page":"2712","volume":"25","author":"G Maor","year":"2016","unstructured":"Maor G, Cabasso O, Krivoruk O, Rodriguez J, Steller H, Segal D, et al. The contribution of mutant GBA to the development of Parkinson disease in Drosophila. Hum Mol Genet. 2016;25:2712\u201327.","journal-title":"Hum Mol Genet"},{"key":"1103_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau K-Y, Hughes D, Mehta A, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137:1481\u201395.","journal-title":"Brain"},{"key":"1103_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Daly L, Bezard E, Schapira AHV. Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice. Ann Neurol. 2016;80:766\u201375.","journal-title":"Ann Neurol"},{"key":"1103_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14:36.","journal-title":"Mol Neurodegener"},{"key":"1103_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","volume":"84","author":"AE Kopytova","year":"2021","unstructured":"Kopytova AE, Rychkov GN, Nikolaev MA, Baydakova GV, Cheblokov AA, Senkevich KA, et al. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism Relat Disord. 2021;84:112\u201321.","journal-title":"Parkinsonism Relat Disord"},{"key":"1103_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ajh.26131","volume":"96","author":"M Istaiti","year":"2021","unstructured":"Istaiti M, Revel-Vilk S, Becker-Cohen M, Dinur T, Ramaswami U, Castillo-Garcia D, et al. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Am J Hematol. 2021;96:545\u201351.","journal-title":"Am J Hematol"},{"key":"1103_CR33","volume-title":"Ambroxol as a novel disease modifying treatment for Parkinson\u2019s disease dementia","author":"S Pasternak","year":"2020","unstructured":"Pasternak S. Ambroxol as a novel disease modifying treatment for Parkinson\u2019s disease dementia: clinicaltrials.gov; 2020. Report no.: NCT02914366. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914366."},{"key":"1103_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","volume":"19","author":"CRA Silveira","year":"2019","unstructured":"Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, et al. Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19:20.","journal-title":"BMC Neurol"},{"key":"1103_CR35","volume-title":"Ambroxol as a novel disease modifying treatment for Lewy body dementia","author":"S Pasternak","year":"2020","unstructured":"Pasternak S. Ambroxol as a novel disease modifying treatment for Lewy body dementia: clinicaltrials.gov; 2020. Report no.: NCT04405596. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405596."},{"key":"1103_CR36","unstructured":"Helse Fonna. A clinical trial to demonstrate clinical efficacy on cognitive, neuropsychiatric and functional outcomes of ambroxol in new and early patients with prodromal and mild dementia with Lewy bodies. clinicaltrials.gov; 2020. Report no.: NCT04588285. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04588285."},{"key":"1103_CR37","doi-asserted-by":"crossref","unstructured":"Bouscary A, Quessada C, Mosbach A, Callizot N, Spedding M, Loeffler J-P, et al. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol. 2019;10 Frontiers. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2019.00883\/full. Cited 2021 Mar 1.","DOI":"10.3389\/fphar.2019.00883"},{"key":"1103_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-019-0266-z","volume":"19","author":"AJ Fowler","year":"2019","unstructured":"Fowler AJ, Hebron M, Missner AA, Wang R, Gao X, Kurd-Misto BT, et al. Multikinase Abl\/DDR\/Src inhibition produces optimal effects for tyrosine kinase inhibition in neurodegeneration. Drugs R D. 2019;19:149\u201366.","journal-title":"Drugs R D"},{"key":"1103_CR39","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/hmg\/ddy365","volume":"28","author":"X Liu","year":"2019","unstructured":"Liu X, Hebron M, Shi W, Lonskaya I, Moussa CE-H. Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies. Hum Mol Genet. 2019;28:548\u201360.","journal-title":"Hum Mol Genet"},{"key":"1103_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.neuroscience.2015.07.070","volume":"304","author":"I Lonskaya","year":"2015","unstructured":"Lonskaya I, Hebron ML, Selby ST, Turner RS, Moussa CE-H. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer\u2019s disease models. Neuroscience. 2015;304:316\u201327.","journal-title":"Neuroscience"},{"key":"1103_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4172\/2155-9899.1000259","volume":"5","author":"ML Hebron","year":"2014","unstructured":"Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE-H. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in \u03b1-synucleinopathy. J Clin Cell Immunol. 2014;5:259.","journal-title":"J Clin Cell Immunol"},{"key":"1103_CR42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4103\/1673-5374.165320","volume":"10","author":"M Hebron","year":"2015","unstructured":"Hebron M, Moussa CE-H. Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration. Neural Regen Res. 2015;10:1767\u20139.","journal-title":"Neural Regen Res"},{"key":"1103_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2018.06.005","volume":"391","author":"ML Hebron","year":"2018","unstructured":"Hebron ML, Javidnia M, Moussa CE-H. Tau clearance improves astrocytic function and brain glutamate-glutamine cycle. J Neurol Sci. 2018;391:90\u20139.","journal-title":"J Neurol Sci"},{"key":"1103_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-020-00364-w","volume":"15","author":"MR Karim","year":"2020","unstructured":"Karim MR, Liao EE, Kim J, Meints J, Martinez HM, Pletnikova O, et al. \u03b1-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener. 2020;15:27.","journal-title":"Mol Neurodegener"},{"key":"1103_CR45","doi-asserted-by":"publisher","first-page":"102031","DOI":"10.1016\/j.pneurobio.2021.102031","volume":"202","author":"LL Barbera","year":"2021","unstructured":"Barbera LL, Vedele F, Nobili A, Krashia P, Spoleti E, Latagliata EC, et al. Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer\u2019s Disease. Prog Neurobiol. 2021;202:102031 Elsevier Limited.","journal-title":"Prog Neurobiol"},{"key":"1103_CR46","doi-asserted-by":"publisher","first-page":"33427","DOI":"10.1038\/srep33427","volume":"6","author":"H Nishioka","year":"2016","unstructured":"Nishioka H, Tooi N, Isobe T, Nakatsuji N, Aiba K. BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer\u2019s disease models. Sci Rep. 2016;6:33427.","journal-title":"Sci Rep"},{"key":"1103_CR47","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/jnc.13763","volume":"139","author":"L Heyburn","year":"2016","unstructured":"Heyburn L, Hebron ML, Smith J, Winston C, Bechara J, Li Z, et al. Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis. J Neurochem. 2016;139:610\u201323.","journal-title":"J Neurochem"},{"key":"1103_CR48","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/mds.28034","volume":"35","author":"M Lopez-Cuina","year":"2020","unstructured":"Lopez-Cuina M, Guerin PA, Canron M-H, Delamarre A, Dehay B, Bezard E, et al. Nilotinib fails to prevent synucleinopathy and cell loss in a mouse model of multiple system atrophy. Mov Disord. 2020;35:1163\u201372.","journal-title":"Mov Disord"},{"key":"1103_CR49","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1021\/ci300367a","volume":"52","author":"F Cheng","year":"2012","unstructured":"Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52:3099\u2013105.","journal-title":"J Chem Inf Model"},{"key":"1103_CR50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77:309\u201317.","journal-title":"JAMA Neurol"},{"key":"1103_CR51","doi-asserted-by":"crossref","unstructured":"Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, et al. Long-Term Safety and Clinical Effects of Nilotinib in Parkinson\u2019s Disease. Mov Disord. 2021;36:740\u20139.","DOI":"10.1002\/mds.28389"},{"key":"1103_CR52","doi-asserted-by":"crossref","unstructured":"Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2021;78:312\u201320.","DOI":"10.1001\/jamaneurol.2020.4725"},{"key":"1103_CR53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.25775","volume":"88","author":"RS Turner","year":"2020","unstructured":"Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer\u2019s disease. Ann Neurol. 2020;88:183\u201394.","journal-title":"Ann Neurol"},{"key":"1103_CR54","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"F Pagan","year":"2016","unstructured":"Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, et al. Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies. J Parkinsons Dis. 2016;6:503\u201317.","journal-title":"J Parkinsons Dis"},{"key":"1103_CR55","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/hmg\/ddaa177","volume":"29","author":"AJ Fowler","year":"2020","unstructured":"Fowler AJ, Hebron M, Balaraman K, Shi W, Missner AA, Greenzaid JD, et al. Discoidin domain receptor 1 is a therapeutic target for neurodegenerative diseases. Hum Mol Genet. 2020;29:2882\u201398.","journal-title":"Hum Mol Genet"},{"key":"1103_CR56","doi-asserted-by":"crossref","first-page":"e12296","DOI":"10.1002\/trc2.12296","volume":"8","author":"FL Pagan","year":"2022","unstructured":"Pagan FL, Torres-Yaghi Y, Hebron ML, Wilmarth B, Turner RS, Matar S, et al. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimers Dement. 2022;8:e12296.","journal-title":"Alzheimers Dement"},{"key":"1103_CR57","volume-title":"Open label study for the use of tyrosine kinase inhibitors for treatment of cognitive decline due to degenerative dementias","author":"S Jordan","year":"2021","unstructured":"Jordan S. Open label study for the use of tyrosine kinase inhibitors for treatment of cognitive decline due to degenerative dementias: clinicaltrials.gov; 2021. Report no.: NCT02921477. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02921477."},{"key":"1103_CR58","unstructured":"MD FP. A randomized, double blind, placebo-controlled study to evaluate the impact of nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in dementia with Lewy bodies (DLB). clinicaltrials.gov; 2021. Report no.: NCT04002674. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04002674."},{"key":"1103_CR59","doi-asserted-by":"crossref","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol. 2021;12:2042018821997320 SAGE Publications.","journal-title":"Ther Adv Endocrinol"},{"issue":"10103","key":"1103_CR60","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375.","journal-title":"Lancet"},{"key":"1103_CR61","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40520-016-0548-z","volume":"28","author":"X Wang","year":"2016","unstructured":"Wang X, Wang L, Xu Y, Yu Q, Li L, Guo Y. Intranasal administration of Exendin-4 antagonizes A\u03b231-35-induced disruption of circadian rhythm and impairment of learning and memory. Aging Clin Exp Res. 2016;28:1259\u201366.","journal-title":"Aging Clin Exp Res"},{"key":"1103_CR62","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.2337\/db14-1718","volume":"64","author":"G Daniele","year":"2015","unstructured":"Daniele G, Iozzo P, Molina-Carrion M, Lancaster J, Ciociaro D, Cersosimo E, et al. Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. Diabetes. 2015;64:3406\u201312.","journal-title":"Diabetes"},{"key":"1103_CR63","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","volume":"42","author":"S Chen","year":"2017","unstructured":"Chen S, Sun J, Zhao G, Guo A, Chen Y, Fu R, et al. Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of Tau and neurofilaments in APP\/PS1\/Tau triple transgenic mice. Neurochem Res. 2017;42:2326\u201335.","journal-title":"Neurochem Res"},{"issue":"1","key":"1103_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jnc.13736","volume":"139","author":"J Jalewa","year":"2016","unstructured":"Jalewa J, Sharma MK, H\u00f6lscher C. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J Neurochem. 2016;139(1):55\u201367.","journal-title":"J Neurochem"},{"issue":"20","key":"1103_CR65","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/ijms20205064","volume":"20","author":"M Bianchi","year":"2019","unstructured":"Bianchi M, D\u2019Oria V, Braghini MR, Petrini S, Manco M. Liraglutide treatment ameliorates neurotoxicity induced by stable silencing of Pin1. Int J Mol Sci. 2019;20(20):5064.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1103_CR66","first-page":"12784","volume":"8","author":"J Zhang","year":"2015","unstructured":"Zhang J, Wu J, Zeng W, Zhao Y, Zu H. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits A\u03b225-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins. Int J Clin Exp Pathol. 2015;8(10):12784\u201392.","journal-title":"Int J Clin Exp Pathol"},{"key":"1103_CR67","doi-asserted-by":"publisher","first-page":"108688","DOI":"10.1016\/j.cbi.2019.06.001","volume":"310","author":"C Zheng","year":"2019","unstructured":"Zheng C, Zhou M, Sun J, Xiong H, Peng P, Gu Z, et al. The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019;310:108688.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"1103_CR68","doi-asserted-by":"publisher","first-page":"16158","DOI":"10.1038\/s41598-017-16488-x","volume":"7","author":"T Panagaki","year":"2017","unstructured":"Panagaki T, Michael M, H\u00f6lscher C. Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. Sci Rep. 2017;7(1):16158.","journal-title":"Sci Rep"},{"key":"1103_CR69","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bcp.2019.05.020","volume":"166","author":"R Dekeryte","year":"2019","unstructured":"Dekeryte R, Hull C, Pluci\u0144ska K, Khan S, Kamli-Salino S, Mody N, et al. Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice. Biochem Pharmacol. 2019;166:222\u201330.","journal-title":"Biochem Pharmacol"},{"key":"1103_CR70","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","volume":"1646","author":"HH Hansen","year":"2016","unstructured":"Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, et al. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson\u2019s disease. Brain Res. 2016;1646:354\u201365.","journal-title":"Brain Res"},{"issue":"2","key":"1103_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/micc.12186","volume":"22","author":"P Kelly","year":"2015","unstructured":"Kelly P, McClean PL, Ackermann M, Konerding MA, H\u00f6lscher C, Mitchell CA. Restoration of cerebral and systemic microvascular architecture in APP\/PS1 transgenic mice following treatment with LiraglutideTM. Microcirculation. 2015;22(2):133\u201345.","journal-title":"Microcirculation"},{"key":"1103_CR72","doi-asserted-by":"publisher","first-page":"101180","DOI":"10.1016\/j.molmet.2021.101180","volume":"47","author":"J Zheng","year":"2021","unstructured":"Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease. Mol Metab. 2021;47:101180.","journal-title":"Mol Metab"},{"key":"1103_CR73","first-page":"e14651","volume":"8","author":"NM Abd el-Rady","year":"2020","unstructured":"Abd el-Rady NM, Ahmed A, Abdel-Rady MM, Ismail OI. Glucagon-like peptide-1 analog improves neuronal and behavioral impairment and promotes neuroprotection in a rat model of aluminum-induced dementia. Physiol Rep. 2020;8:e14651.","journal-title":"Physiol Rep"},{"key":"1103_CR74","doi-asserted-by":"publisher","first-page":"E860","DOI":"10.3390\/ijms22020860","volume":"22","author":"L Paladugu","year":"2021","unstructured":"Paladugu L, Gharaibeh A, Kolli N, Learman C, Hall TC, Li L, et al. Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer\u2019s disease. Int J Mol Sci. 2021;22:E860.","journal-title":"Int J Mol Sci"},{"key":"1103_CR75","doi-asserted-by":"publisher","first-page":"661","DOI":"10.17219\/acem\/121007","volume":"29","author":"CJ Yu","year":"2020","unstructured":"Yu CJ, Ma D, Song LL, Zhai ZN, Tao Y, Zhang Y, et al. The role of GLP-1\/GIP receptor agonists in Alzheimer\u2019s disease. Adv Clin Exp Med. 2020;29:661\u20138.","journal-title":"Adv Clin Exp Med"},{"key":"1103_CR76","doi-asserted-by":"publisher","first-page":"153331752095304","DOI":"10.1177\/1533317520953041","volume":"35","author":"M Maskery","year":"2020","unstructured":"Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, H\u00f6lscher C. The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Am J Alzheimers Dis Other Dement. 2020;35:1533317520953041 SAGE Publications Inc.","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"1103_CR77","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","volume":"202","author":"S Kim","year":"2009","unstructured":"Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease. J Endocrinol. 2009;202:431\u20139.","journal-title":"J Endocrinol"},{"issue":"4","key":"1103_CR78","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol. 2019;76(4):420\u20139.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1103_CR79","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/00207454.2018.1543671","volume":"129","author":"A Khalilnezhad","year":"2019","unstructured":"Khalilnezhad A, Taskiran D. The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity. Int J Neurosci. 2019;129(5):481\u201391.","journal-title":"Int J Neurosci"},{"issue":"5","key":"1103_CR80","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1038\/cddis.2013.139","volume":"4","author":"M Bomba","year":"2013","unstructured":"Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis. 2013;4(5):e612.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1103_CR81","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jnr.10611","volume":"72","author":"T Perry","year":"2003","unstructured":"Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003;72(5):603\u201312.","journal-title":"J Neurosci Res"},{"key":"1103_CR82","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3233\/JAD-190237","volume":"70","author":"M Bomba","year":"2019","unstructured":"Bomba M, Granzotto A, Castelli V, Onofrj M, Lattanzio R, Cimini A, et al. Exenatide reverts the high-fat-diet-induced impairment of BDNF signaling and inflammatory response in an animal model of Alzheimer\u2019s disease. J Alzheimers Dis. 2019;70:793\u2013810.","journal-title":"J Alzheimers Dis"},{"key":"1103_CR83","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41467-020-18249-3","volume":"11","author":"L Zhao","year":"2020","unstructured":"Zhao L, Li Z, Vong JSL, Chen X, Lai H-M, Yan LYC, et al. Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain. Nat Commun. 2020;11:4413.","journal-title":"Nat Commun"},{"key":"1103_CR84","doi-asserted-by":"publisher","first-page":"113693","DOI":"10.1016\/j.expneurol.2021.113693","volume":"341","author":"L Bergkvist","year":"2021","unstructured":"Bergkvist L, Johnson ME, Mercado G, Steiner JA, Meyerdirk L, Schulz E, et al. An extended release GLP-1 analogue increases \u03b1-synuclein accumulation in a mouse model of prodromal Parkinson\u2019s disease. Exp Neurol. 2021;341:113693.","journal-title":"Exp Neurol"},{"key":"1103_CR85","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","volume":"8","author":"D Athauda","year":"2018","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, et al. What effects might exenatide have on non-motor symptoms in Parkinson\u2019s disease: a post hoc analysis. J Parkinsons Dis. 2018;8:247\u201358.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1103_CR86","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ejn.14096","volume":"49","author":"D Athauda","year":"2019","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, et al. Post hoc analysis of the exenatide-PD trial-factors that predict response. Eur J Neurosci. 2019a;49(3):410\u201321.","journal-title":"Eur J Neurosci"},{"issue":"6","key":"1103_CR87","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest. 2013;123(6):2730\u20136.","journal-title":"J Clin Invest"},{"key":"1103_CR88","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J Parkinsons Dis. 2014;4:337\u201344.","journal-title":"J Parkinsons Dis"},{"key":"1103_CR89","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.3390\/ijerph17134805","volume":"17","author":"S-Y Wang","year":"2020","unstructured":"Wang S-Y, Wu S-L, Chen T-C, Chuang C-S. Antidiabetic agents for treatment of Parkinson\u2019s disease: a meta-analysis. Int J Environ Res Public Health. 2020;17:4805.","journal-title":"Int J Environ Res Public Health"},{"key":"1103_CR90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, et al. Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav Brain Res. 2019;356:271\u20138.","journal-title":"Behav Brain Res"},{"key":"1103_CR91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, M\u00f8ller A, Hansen SB, Vang K, et al. 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.","journal-title":"Front Aging Neurosci"},{"key":"1103_CR92","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/1567205016666190913155950","volume":"16","author":"RJ Mullins","year":"2019","unstructured":"Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, et al. A pilot study of exenatide actions in Alzheimer\u2019s disease. Curr Alzheimer Res. 2019;16:741\u201352.","journal-title":"Curr Alzheimer Res"},{"key":"1103_CR93","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/mds.26734","volume":"31","author":"P Svenningsson","year":"2016","unstructured":"Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, et al. Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study. Mov Disord. 2016;31:1422\u20133.","journal-title":"Mov Disord"},{"key":"1103_CR94","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T, Athauda D, Girges C, Vijiaratnam N, et al. Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain. 2020;143:3067\u201376.","journal-title":"Brain"},{"key":"1103_CR95","doi-asserted-by":"publisher","first-page":"i436","DOI":"10.1093\/bioinformatics\/btaa451","volume":"36","author":"M Zhou","year":"2020","unstructured":"Zhou M, Zheng C, Xu R. Combining phenome-driven drug-target interaction prediction with patients\u2019 electronic health records-based clinical corroboration toward drug discovery. Bioinformatics. 2020;36:i436\u201344.","journal-title":"Bioinformatics"},{"key":"1103_CR96","doi-asserted-by":"publisher","first-page":"153331751989954","DOI":"10.1177\/1533317519899546","volume":"35","author":"H Akimoto","year":"2020","unstructured":"Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N, et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. Am J Alzheimers Dis Other Dement. 2020;35:1533317519899546.","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"1103_CR97","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"GD Femminella","year":"2019","unstructured":"Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019;20:191.","journal-title":"Trials"},{"key":"1103_CR98","first-page":"A4519","volume":"59","author":"L Egefjord","year":"2012","unstructured":"Egefjord L, Gejl M, M\u00f8ller A, Br\u00e6ndgaard H, Gottrup H, Antropova O, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer\u2019s disease - protocol for a controlled, randomized double-blinded trial. Dan Med J. 2012;59:A4519.","journal-title":"Dan Med J"},{"key":"1103_CR99","volume-title":"A randomised, double blind, parallel group, placebo controlled, phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson\u2019s disease","author":"University College, London","year":"2021","unstructured":"University College, London. A randomised, double blind, parallel group, placebo controlled, phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson\u2019s disease: clinicaltrials.gov; 2021. Report no.: NCT04232969. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04232969."},{"key":"1103_CR100","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2008.04.010","volume":"202","author":"MR Dasu","year":"2009","unstructured":"Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis. 2009;202:76\u201383.","journal-title":"Atherosclerosis"},{"key":"1103_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2019.06.042","volume":"81","author":"A Kouli","year":"2019","unstructured":"Kouli A, Horne CB, Williams-Gray CH. Toll-like receptors and their therapeutic potential in Parkinson\u2019s disease and \u03b1-synucleinopathies. Brain Behav Immun. 2019;81:41\u201351.","journal-title":"Brain Behav Immun"},{"issue":"376","key":"1103_CR102","doi-asserted-by":"publisher","first-page":"ra45","DOI":"10.1126\/scisignal.2005965","volume":"8","author":"SG Daniele","year":"2015","unstructured":"Daniele SG, B\u00e9raud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA. Activation of MyD88-dependent TLR1\/2 signaling by misfolded \u03b1-synuclein, a protein linked to neurodegenerative disorders. Sci Signal. 2015;8(376):ra45.","journal-title":"Sci Signal"},{"issue":"1","key":"1103_CR103","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/glia.22595","volume":"62","author":"A Borrajo","year":"2014","unstructured":"Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-\u03b1 mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014;62(1):145\u201357.","journal-title":"Glia"},{"issue":"4","key":"1103_CR104","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s13311-018-0646-z","volume":"15","author":"AI Rodriguez-Perez","year":"2018","unstructured":"Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, et al. Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death. Neurotherapeutics. 2018;15(4):1063\u201381.","journal-title":"Neurotherapeutics"},{"key":"1103_CR105","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejphar.2016.02.042","volume":"776","author":"Q Tong","year":"2016","unstructured":"Tong Q, Wu L, Jiang T, Ou Z, Zhang Y, Zhu D. Inhibition of endoplasmic reticulum stress-activated IRE1\u03b1-TRAF2-caspase-12 apoptotic pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson\u2019s disease. Eur J Pharmacol. 2016;776:106\u201315.","journal-title":"Eur J Pharmacol"},{"key":"1103_CR106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuropharm.2013.05.025","volume":"73","author":"S Sathiya","year":"2013","unstructured":"Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, et al. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of \u03b1-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL\/6J mice. Neuropharmacology. 2013;73:98\u2013110.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1103_CR107","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12640-018-9921-3","volume":"34","author":"S Sekar","year":"2018","unstructured":"Sekar S, Mani S, Rajamani B, Manivasagam T, Thenmozhi AJ, Bhat A, et al. Telmisartan ameliorates astroglial and dopaminergic functions in a mouse model of chronic parkinsonism. Neurotox Res. 2018;34(3):597\u2013612.","journal-title":"Neurotox Res"},{"key":"1103_CR108","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.neulet.2013.06.008","volume":"548","author":"L Wu","year":"2013","unstructured":"Wu L, Tian YY, Shi JP, Xie W, Shi JQ, Lu J, et al. Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson\u2019s disease. Neurosci Lett. 2013;548:50\u20135.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1103_CR109","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/1470320312459977","volume":"14","author":"B Singh","year":"2013","unstructured":"Singh B, Sharma B, Jaggi AS, Singh N. Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer\u2019s disease type: possible involvement of PPAR-\u03b3 agonistic property. J Renin-Angiotensin-Aldosterone Syst. 2013;14(2):124\u201336.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"3","key":"1103_CR110","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/cns.12802","volume":"24","author":"N Torika","year":"2018","unstructured":"Torika N, Asraf K, Apte RN, Fleisher-Berkovich S. Candesartan ameliorates brain inflammation associated with Alzheimer\u2019s disease. CNS Neurosci Ther. 2018;24(3):231\u201342.","journal-title":"CNS Neurosci Ther"},{"key":"1103_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2009-0925","volume":"16","author":"W Zhao","year":"2009","unstructured":"Zhao W, Wang J, Ho L, Ono K, Teplow DB, Pasinetti GM. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J Alzheimers Dis. 2009;16:49\u201357.","journal-title":"J Alzheimers Dis"},{"key":"1103_CR112","doi-asserted-by":"publisher","first-page":"117388","DOI":"10.1016\/j.lfs.2020.117388","volume":"245","author":"NF Abdelkader","year":"2020","unstructured":"Abdelkader NF, Abd El-Latif AM, Khattab MM. Telmisartan\/17\u03b2-estradiol mitigated cognitive deficit in an ovariectomized rat model of Alzheimer\u2019s disease: modulation of ACE1\/ACE2 and AT1\/AT2 ratio. Life Sci. 2020;245:117388.","journal-title":"Life Sci"},{"issue":"3","key":"1103_CR113","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","volume":"375","author":"M Mogi","year":"2008","unstructured":"Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun. 2008;375(3):446\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1103_CR114","doi-asserted-by":"publisher","first-page":"113674","DOI":"10.1016\/j.bcp.2019.113674","volume":"171","author":"ZF Wang","year":"2020","unstructured":"Wang ZF, Li J, Ma C, Huang C, Li ZQ. Telmisartan ameliorates A\u03b2 oligomer-induced inflammation via PPAR\u03b3\/PTEN pathway in BV2 microglial cells. Biochem Pharmacol. 2020;171:113674.","journal-title":"Biochem Pharmacol"},{"key":"1103_CR115","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuropharm.2013.07.016","volume":"76 Pt A","author":"A Dominguez-Meijide","year":"2014","unstructured":"Dominguez-Meijide A, Villar-Cheda B, Garrido-Gil P, Sierrra-Paredes G, Guerra MJ, Labandeira-Garcia JL. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson\u2019s disease treated with L-DOPA. Neuropharmacology. 2014;76 Pt A:156\u201368.","journal-title":"Neuropharmacology"},{"issue":"5","key":"1103_CR116","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1161\/HYPERTENSIONAHA.118.11775","volume":"72","author":"LJ Trigiani","year":"2018","unstructured":"Trigiani LJ, Royea J, Lacalle-Aurioles M, Tong XK, Hamel E. Pleiotropic benefits of the angiotensin receptor blocker candesartan in a mouse model of Alzheimer disease. Hypertension. 2018;72(5):1217\u201326.","journal-title":"Hypertension"},{"key":"1103_CR117","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1248\/bpb.b20-00007","volume":"43","author":"K Kikuchi","year":"2020","unstructured":"Kikuchi K, Fujita Y, Shen X, Liu J, Terakawa T, Nishikata D, et al. Interaction between angiotensin receptor and \u03b2-adrenergic receptor regulates the production of amyloid \u03b2-protein. Biol Pharm Bull. 2020;43:731\u20135.","journal-title":"Biol Pharm Bull"},{"key":"1103_CR118","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archinternmed.2011.1391","volume":"172","author":"I Hajjar","year":"2012","unstructured":"Hajjar I, Hart M, Chen Y-L, Mack W, Milberg W, Chui H, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med. 2012;172:442\u20134.","journal-title":"Arch Intern Med"},{"key":"1103_CR119","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/jgs.12100","volume":"61","author":"I Hajjar","year":"2013","unstructured":"Hajjar I, Hart M, Chen Y-L, Mack W, Novak V, Chui HC, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc. 2013;61:194\u2013201.","journal-title":"J Am Geriatr Soc"},{"key":"1103_CR120","doi-asserted-by":"publisher","first-page":"e2012252","DOI":"10.1001\/jamanetworkopen.2020.12252","volume":"3","author":"I Hajjar","year":"2020","unstructured":"Hajjar I, Okafor M, McDaniel D, Obideen M, Dee E, Shokouhi M, et al. Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial. JAMA Netw Open. 2020;3:e2012252.","journal-title":"JAMA Netw Open"},{"key":"1103_CR121","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/01.wnl.0000311447.85948.78","volume":"70","author":"BK Saxby","year":"2008","unstructured":"Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. 2008;70:1858\u201366.","journal-title":"Neurology"},{"key":"1103_CR122","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875\u201386.","journal-title":"J Hypertens"},{"key":"1103_CR123","doi-asserted-by":"publisher","first-page":"b5465","DOI":"10.1136\/bmj.b5465","volume":"340","author":"N-C Li","year":"2010","unstructured":"Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.","journal-title":"BMJ"},{"key":"1103_CR124","volume-title":"Candesartan\u2019s effects on Alzheimer\u2019s disease and related biomarkers","author":"I Hajjar","year":"2021","unstructured":"Hajjar I. Candesartan\u2019s effects on Alzheimer\u2019s disease and related biomarkers: clinicaltrials.gov; 2021. Report no.: NCT02646982. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02646982."},{"key":"1103_CR125","volume-title":"The SARTAN-AD trial: a randomized, open label, proof of concept study of telmisartan vs. perindopril in mild-moderate Alzheimer\u2019s disease patients","author":"DSE Black","year":"2020","unstructured":"Black DSE. The SARTAN-AD trial: a randomized, open label, proof of concept study of telmisartan vs. perindopril in mild-moderate Alzheimer\u2019s disease patients: clinicaltrials.gov; 2020. Report no.: NCT02085265. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02085265."},{"key":"1103_CR126","volume-title":"Health evaluation in African Americans using RAS therapy","author":"W Wharton","year":"2021","unstructured":"Wharton W. Health evaluation in African Americans using RAS therapy: clinicaltrials.gov; 2021. Report no.: NCT02471833. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02471833."},{"key":"1103_CR127","unstructured":"Glucophage 500 mg film coated tablets Summary of Product Characteristics. 2020. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/987\/smpc.\u00a0Accessed 17 Jan 2022."},{"key":"1103_CR128","doi-asserted-by":"crossref","unstructured":"Saewanee N, Praputpittaya T, Malaiwong N, Chalorak P, Meemon K. Neuroprotective effect of metformin on dopaminergic neurodegeneration and \u03b1-synuclein aggregation in C. elegans model of Parkinson\u2019s disease. Neurosci Res. 2021;162:13\u201321.","DOI":"10.1016\/j.neures.2019.12.017"},{"key":"1103_CR129","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","volume":"125","author":"N Katila","year":"2017","unstructured":"Katila N, Bhurtel S, Shadfar S, Srivastav S, Neupane S, Ojha U, et al. Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology. 2017;125:396\u2013407.","journal-title":"Neuropharmacology"},{"key":"1103_CR130","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fncel.2018.00440","volume":"12","author":"K Tayara","year":"2018","unstructured":"Tayara K, Espinosa-Oliva AM, Garc\u00eda-Dom\u00ednguez I, Ismaiel AA, Boza-Serrano A, Deierborg T, et al. Divergent effects of metformin on an inflammatory model of Parkinson\u2019s disease. Front Cell Neurosci. 2018;12:440.","journal-title":"Front Cell Neurosci"},{"key":"1103_CR131","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s43440-020-00095-1","volume":"72","author":"G Ozbey","year":"2020","unstructured":"Ozbey G, Nemutlu-Samur D, Parlak H, Yildirim S, Aslan M, Tanriover G, et al. Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation. Pharmacol Rep. 2020;72:1397\u2013406.","journal-title":"Pharmacol Rep"},{"key":"1103_CR132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-020-00761-9","volume":"13","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhao S, Fan Z, Li Z, Zhu Y, Shen T, et al. Metformin attenuates plaque-associated tau pathology and reduces amyloid-\u03b2 burden in APP\/PS1 mice. Alzheimers Res Ther. 2021;13:40.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1103_CR133","doi-asserted-by":"publisher","first-page":"e1209","DOI":"10.1038\/cddis.2014.175","volume":"5","author":"BI P\u00e9rez-Revuelta","year":"2014","unstructured":"P\u00e9rez-Revuelta BI, Hettich MM, Ciociaro A, Rotermund C, Kahle PJ, Krauss S, et al. Metformin lowers Ser-129 phosphorylated \u03b1-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis. 2014;5(5):e1209.","journal-title":"Cell Death Dis"},{"key":"1103_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2013.11.002","volume":"63","author":"M Dulovic","year":"2014","unstructured":"Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, et al. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol Dis. 2014;63:1\u201311.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"1103_CR135","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1124\/mol.117.109512","volume":"92","author":"Q Yan","year":"2017","unstructured":"Yan Q, Han C, Wang G, Waddington JL, Zheng L, Zhen X. Activation of AMPK\/mTORC1-mediated autophagy by metformin reverses Clk1 deficiency-sensitized dopaminergic neuronal death. Mol Pharmacol. 2017;92(6):640\u201352.","journal-title":"Mol Pharmacol"},{"key":"1103_CR136","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/15376516.2020.1741053","volume":"30","author":"D-X Wang","year":"2020","unstructured":"Wang D-X, Chen A-D, Wang Q-J, Xin Y-Y, Yin J, Jing Y-H. Protective effect of metformin against rotenone-induced parkinsonism in mice. Toxicol Mech Methods. 2020;30:350\u20137.","journal-title":"Toxicol Mech Methods"},{"key":"1103_CR137","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pnpbp.2013.10.014","volume":"48","author":"HA Adedeji","year":"2014","unstructured":"Adedeji HA, Ishola IO, Adeyemi OO. Novel action of metformin in the prevention of haloperidol-induced catalepsy in mice: potential in the treatment of Parkinson\u2019s disease? Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:245\u201351.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1103_CR138","first-page":"812","volume":"18","author":"P Chanthammachat","year":"2019","unstructured":"Chanthammachat P, Dharmasaroja P. Metformin restores the mitochondrial membrane potentials in association with a reduction in TIMM23 and NDUFS3 in MPP+-induced neurotoxicity in SH-SY5Y cells. EXCLI J. 2019;18:812\u201323.","journal-title":"EXCLI J"},{"key":"1103_CR139","doi-asserted-by":"publisher","first-page":"117861","DOI":"10.1016\/j.lfs.2020.117861","volume":"255","author":"PM Saffari","year":"2020","unstructured":"Saffari PM, Alijanpour S, Takzaree N, Sahebgharani M, Etemad-Moghadam S, Noorbakhsh F, et al. Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer\u2019s disease model. Life Sci. 2020;255:117861.","journal-title":"Life Sci"},{"key":"1103_CR140","doi-asserted-by":"publisher","first-page":"2315106","DOI":"10.1155\/2020\/2315106","volume":"2020","author":"X-Y Lu","year":"2020","unstructured":"Lu X-Y, Huang S, Chen Q-B, Zhang D, Li W, Ao R, et al. Metformin ameliorates A\u03b2 pathology by insulin-degrading enzyme in a transgenic mouse model of Alzheimer\u2019s disease. Oxidative Med Cell Longev. 2020;2020:2315106.","journal-title":"Oxidative Med Cell Longev"},{"key":"1103_CR141","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2337\/db19-1128","volume":"69","author":"K Jinawong","year":"2020","unstructured":"Jinawong K, Apaijai N, Wongsuchai S, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Necrostatin-1 mitigates cognitive dysfunction in prediabetic rats with no alteration in insulin sensitivity. Diabetes. 2020;69:1411\u201323.","journal-title":"Diabetes"},{"key":"1103_CR142","doi-asserted-by":"crossref","unstructured":"Nie J, J iang L-S, Zhang Y, Tian Y, Li L-S, Lu Y-L, et al. Dendrobium nobile Lindl. Alkaloids Decreases the Level of Intracellular \u03b2-Amyloid by Improving Impaired Autolysosomal Proteolysis in APP\/PS1 Mice. Front Pharmacol. 2018;9:1479.","DOI":"10.3389\/fphar.2018.01479"},{"key":"1103_CR143","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","volume":"69","author":"Z Ou","year":"2018","unstructured":"Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice. Brain Behav Immun. 2018;69:351\u201363.","journal-title":"Brain Behav Immun"},{"key":"1103_CR144","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3233\/JAD-200308","volume":"76","author":"L-L Lv","year":"2020","unstructured":"Lv L-L, Liu B, Liu J, Li L-S, Jin F, Xu Y-Y, et al. Dendrobium nobile Lindl. Alkaloids ameliorate cognitive dysfunction in senescence accelerated SAMP8 mice by decreasing Amyloid-\u03b2 aggregation and enhancing autophagy activity. J Alzheimers Dis. 2020;76:657\u201369.","journal-title":"J Alzheimers Dis"},{"key":"1103_CR145","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3233\/JAD-181017","volume":"68","author":"A Kuhla","year":"2019","unstructured":"Kuhla A, Brichmann E, R\u00fchlmann C, Thiele R, Meuth L, Vollmar B. Metformin therapy aggravates neurodegenerative processes in ApoE-\/- mice. J Alzheimers Dis. 2019;68:1415\u201327.","journal-title":"J Alzheimers Dis"},{"issue":"30","key":"1103_CR146","doi-asserted-by":"publisher","first-page":"48603","DOI":"10.18632\/oncotarget.18122","volume":"8","author":"H Kang","year":"2017","unstructured":"Kang H, Khang R, Ham S, Jeong GR, Kim H, Jo M, et al. Activation of the ATF2\/CREB-PGC-1\u03b1 pathway by metformin leads to dopaminergic neuroprotection. Oncotarget. 2017;8(30):48603\u201318.","journal-title":"Oncotarget"},{"key":"1103_CR147","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.taap.2016.03.004","volume":"298","author":"AA Ismaiel","year":"2016","unstructured":"Ismaiel AA, Espinosa-Oliva AM, Santiago M, Garc\u00eda-Quintanilla A, Oliva-Mart\u00edn MJ, Herrera AJ, et al. Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system. Toxicol Appl Pharmacol. 2016;298:19\u201330.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1103_CR148","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3233\/JAD-170440","volume":"60","author":"R Karki","year":"2017","unstructured":"Karki R, Kodamullil AT, Hofmann-Apitius M. Comorbidity analysis between Alzheimer\u2019s disease and type 2 diabetes mellitus (T2DM) based on shared pathways and the role of T2DM drugs. J Alzheimers Dis. 2017;60:721\u201331.","journal-title":"J Alzheimers Dis"},{"key":"1103_CR149","doi-asserted-by":"crossref","unstructured":"Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study. Alzheimer Dis Assoc Disord. 2017;31:107\u201313.","DOI":"10.1097\/WAD.0000000000000202"},{"key":"1103_CR150","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JAD-150493","volume":"51","author":"JA Luchsinger","year":"2016","unstructured":"Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomised placebo controlled clinical trial. J Alzheimers Dis. 2016;51:501\u201314.","journal-title":"J Alzheimers Dis"},{"key":"1103_CR151","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fnagi.2018.00227","volume":"10","author":"Y Lin","year":"2018","unstructured":"Lin Y, Wang K, Ma C, Wang X, Gong Z, Zhang R, et al. Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci. 2018;10:227.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"1103_CR152","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","volume":"18","author":"ML Wahlqvist","year":"2012","unstructured":"Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson\u2019s disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18(6):753\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"1103_CR153","doi-asserted-by":"crossref","unstructured":"Sluggett JK, Koponen M, Bell JS, Taipale H, Tanskanen A, Tiihonen J, et al. Metformin and Risk of Alzheimer\u2019s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. J Clin Endocrinol Metab. 2020;105:dgz234.","DOI":"10.1210\/clinem\/dgz234"},{"issue":"2","key":"1103_CR154","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ana.24439","volume":"78","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284\u201394.","journal-title":"Ann Neurol"},{"key":"1103_CR155","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.2337\/dc20-0892","volume":"43","author":"K Samaras","year":"2020","unstructured":"Samaras K, Makkar S, Crawford JD, Kochan NA, Wen W, Draper B, et al. Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study. Diabetes Care. 2020;43:2691\u2013701.","journal-title":"Diabetes Care"},{"key":"1103_CR156","doi-asserted-by":"publisher","first-page":"154265","DOI":"10.1016\/j.metabol.2020.154265","volume":"109","author":"J-B Zhou","year":"2020","unstructured":"Zhou J-B, Tang X, Han M, Yang J, Sim\u00f3 R. Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis. Metabolism. 2020;109:154265.","journal-title":"Metabolism"},{"key":"1103_CR157","doi-asserted-by":"publisher","first-page":"108496","DOI":"10.1016\/j.diabres.2020.108496","volume":"170","author":"Y Kim","year":"2020","unstructured":"Kim Y, Kim H-S, Lee J-W, Kim Y-S, You H-S, Bae Y-J, et al. Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. Diabetes Res Clin Pract. 2020;170:108496.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1103_CR158","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","volume":"60","author":"P Imfeld","year":"2012","unstructured":"Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: a population-based case-control study. J Am Geriatr Soc. 2012;60(5):916\u201321.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1103_CR159","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diabres.2010.10.006","volume":"91","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Vitry A, Caughey G, Roughead EE, Ryan P, Gilbert A, et al. The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes. Diabetes Res Clin Pract. 2011;91(1):115\u201320.","journal-title":"Diabetes Res Clin Pract"},{"key":"1103_CR160","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/pds.5014","volume":"29","author":"J Salas","year":"2020","unstructured":"Salas J, Morley JE, Scherrer JF, Floyd JS, Farr SA, Zubatsky M, et al. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. Pharmacoepidemiol Drug Saf. 2020;29:623\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1103_CR161","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/alz.12161","volume":"16","author":"C-Y Wu","year":"2020","unstructured":"Wu C-Y, Ouk M, Wong YY, Anita NZ, Edwards JD, Yang P, et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer\u2019s disease, and the role APOE carrier status. Alzheimers Dement. 2020;16:1663\u201373.","journal-title":"Alzheimers Dement"},{"key":"1103_CR162","doi-asserted-by":"publisher","first-page":"e001370","DOI":"10.1136\/bmjdrc-2020-001370","volume":"8","author":"F Ping","year":"2020","unstructured":"Ping F, Jiang N, Li Y. Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2020;8:e001370.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1103_CR163","volume-title":"Metformin in Alzheimer\u2019s dementia prevention","author":"JA Luchsinger","year":"2021","unstructured":"Luchsinger JA. Metformin in Alzheimer\u2019s dementia prevention: clinicaltrials.gov; 2021. Report no.: NCT04098666. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04098666."},{"key":"1103_CR164","unstructured":"Luchsinger JA. Amyloid brain positron emission tomography (PET) imaging with 11C-PIB and Tau PET imaging with 18F-MK-6240 in the Diabetes Prevention Program Outcomes Study. clinicaltrials.gov; 2021. Report no.: NCT03757910. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03757910."},{"key":"1103_CR165","unstructured":"University of Pennsylvania. A phase II trial to study the effect of metformin on AD biomarkers: a randomized placebo controlled crossover pilot study of metformin effects on cognitive, physiological and biochemical biomarkers of MCI and dementia due to AD. clinicaltrials.gov; 2017. Report no.: NCT01965756. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01965756."},{"key":"1103_CR166","volume-title":"Preventing cognitive decline with metformin:: the MetMemory Study","author":"Garvan Institute of Medical Research","year":"2021","unstructured":"Garvan Institute of Medical Research. Preventing cognitive decline with metformin:: the MetMemory Study: clinicaltrials.gov; 2021. Report no.: NCT04511416. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04511416."},{"key":"1103_CR167","unstructured":"Han AWK. Insulin resistance and mild cognitive impairment (MCI) in older Chinese adults with pre-diabetes and diabetes: cognitive effects of lifestyle intervention and metformin treatment in a randomized controlled trial. clinicaltrials.gov; 2016. Report no.: NCT02409238. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02409238."},{"key":"1103_CR168","volume-title":"Metformin effect on brain function in insulin resistant elderly people","author":"KS Nair","year":"2021","unstructured":"Nair KS. Metformin effect on brain function in insulin resistant elderly people: clinicaltrials.gov; 2021. Report no.: NCT03733132. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03733132."},{"issue":"2","key":"1103_CR169","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.10.006","volume":"14","author":"Y Hanada","year":"2005","unstructured":"Hanada Y, Kudo H, Kohmura E. Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2005;14(2):47\u20139.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"5","key":"1103_CR170","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd1719","volume":"4","author":"BK Mueller","year":"2005","unstructured":"Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4(5):387\u201398.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1103_CR171","first-page":"894","volume":"48","author":"Y Takanashi","year":"2001","unstructured":"Takanashi Y, Ishida T, Meguro T, Kiwada H, Zhang JH, Yamamoto I. Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery. 2001;48(4):894\u2013900:900\u20131.","journal-title":"Neurosurgery"},{"key":"1103_CR172","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0378-5173(01)00896-1","volume":"232","author":"T Ishida","year":"2002","unstructured":"Ishida T, Takanashi Y, Doi H, Yamamoto I, Kiwada H. Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharm. 2002;232:59\u201367.","journal-title":"Int J Pharm"},{"key":"1103_CR173","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.brainres.2015.12.002","volume":"1632","author":"FT Liu","year":"2016","unstructured":"Liu FT, Yang YJ, Wu JJ, Li S, Tang YL, Zhao J, et al. Fasudil, a Rho kinase inhibitor, promotes the autophagic degradation of A53T \u03b1-synuclein by activating the JNK 1\/Bcl-2\/beclin 1 pathway. Brain Res. 2016;1632:9\u201318.","journal-title":"Brain Res"},{"issue":"3","key":"1103_CR174","first-page":"2354","volume":"8","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Zhang Q, Xi J, Xiao B, Li Y, Ma C. Neuroprotective effect of fasudil on inflammation through PI3K\/Akt and Wnt\/\u03b2-catenin dependent pathways in a mice model of Parkinson\u2019s disease. Int J Clin Exp Pathol. 2015;8(3):2354\u201364.","journal-title":"Int J Clin Exp Pathol"},{"key":"1103_CR175","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-016-0310-y","volume":"4","author":"L Tatenhorst","year":"2016","unstructured":"Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Fonseca T, et al. Fasudil attenuates aggregation of \u03b1-synuclein in models of Parkinson\u2019s disease. Acta Neuropathol Commun. 2016;4:39.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1103_CR176","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejn.13132","volume":"43","author":"Q He","year":"2016","unstructured":"He Q, Li YH, Guo SS, Wang Y, Lin W, Zhang Q, et al. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson\u2019s model. Eur J Neurosci. 2016;43(1):41\u201352.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"1103_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-018-0231-6","volume":"8","author":"C Elliott","year":"2018","unstructured":"Elliott C, Rojo AI, Ribe E, Broadstock M, Xia W, Morin P, et al. A role for APP in Wnt signalling links synapse loss with \u03b2-amyloid production. Transl Psychiatry. 2018;8(1):1\u20133.","journal-title":"Transl Psychiatry"},{"key":"1103_CR178","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbr.2018.05.024","volume":"351","author":"M Kumar","year":"2018","unstructured":"Kumar M, Bansal N. Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer\u2019s disease: involvement of PI3-kinase, eNOS and NF\u03baB. Behav Brain Res. 2018;351:4\u201316.","journal-title":"Behav Brain Res"},{"issue":"48","key":"1103_CR179","doi-asserted-by":"publisher","first-page":"10349","DOI":"10.1523\/JNEUROSCI.1409-18.2018","volume":"38","author":"T Rush","year":"2018","unstructured":"Rush T, Martinez-Hernandez J, Dollmeyer M, Frandemiche ML, Borel E, Boisseau S, et al. Synaptotoxicity in Alzheimer\u2019s disease involved a dysregulation of actin cytoskeleton dynamics through cofilin 1 phosphorylation. J Neurosci. 2018;38(48):10349\u201361.","journal-title":"J Neurosci"},{"key":"1103_CR180","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fnagi.2018.00216","volume":"10","author":"J Yu","year":"2018","unstructured":"Yu J, Yan Y, Gu Q, Kumar G, Yu H, Zhao Y, et al. Fasudil in combination with bone marrow stromal cells (BMSCs) attenuates Alzheimer\u2019s disease-related changes through the regulation of the peripheral immune system. Front Aging Neurosci. 2018;10:216.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1103_CR181","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11011-018-0355-7","volume":"34","author":"Y Yan","year":"2019","unstructured":"Yan Y, Yu J, Gao Y, Kumar G, Guo M, Zhao Y, et al. Therapeutic potentials of the Rho kinase inhibitor Fasudil in experimental autoimmune encephalomyelitis and the related mechanisms. Metab Brain Dis. 2019;34(2):377\u201384.","journal-title":"Metab Brain Dis"},{"key":"1103_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.03.008","volume":"189","author":"JC Koch","year":"2018","unstructured":"Koch JC, Tatenhorst L, Roser AE, Saal KA, T\u00f6nges L, Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018;189:1\u201321.","journal-title":"Pharmacol Ther"},{"issue":"17","key":"1103_CR183","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1073\/pnas.1616024114","volume":"114","author":"V Bobo-Jim\u00e9nez","year":"2017","unstructured":"Bobo-Jim\u00e9nez V, Delgado-Esteban M, Angibaud J, S\u00e1nchez-Mor\u00e1n I, Fuente A, Yajeya J, et al. APC\/CCdh1-Rock2 pathway controls dendritic integrity and memory. Proc Natl Acad Sci U S A. 2017;114(17):4513\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1103_CR184","volume-title":"Inhibition of Rho Kinase (ROCK) With fasudil as disease-modifying treatment for ALS","author":"P Lingor","year":"2020","unstructured":"Lingor P. Inhibition of Rho Kinase (ROCK) With fasudil as disease-modifying treatment for ALS: clinicaltrials.gov; 2020. Report no.: NCT03792490. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03792490."},{"key":"1103_CR185","unstructured":"Woolsey Pharmaceuticals. A phase 2a open-label preliminary safety, tolerability, and biomarker study of oral fasudil in patients with the 4-repeat tauopathies of progressive supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome. clinicaltrials.gov; 2021. Report no.: NCT04734379. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04734379."},{"issue":"1","key":"1103_CR186","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1176\/appi.neuropsych.15050118","volume":"29","author":"LL Frakey","year":"2017","unstructured":"Frakey LL, Friedman JH. Cognitive effects of rasagiline in mild-to-moderate stage Parkinson\u2019s disease without dementia. J Neuropsychiatr Clin Neurosci. 2017;29(1):22\u20135.","journal-title":"J Neuropsychiatr Clin Neurosci"},{"issue":"4","key":"1103_CR187","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/mds.26124","volume":"30","author":"W Poewe","year":"2015","unstructured":"Poewe W, Hauser RA, Lang A, Investigators ADAGIO. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord. 2015;30(4):589\u201392.","journal-title":"Mov Disord"},{"issue":"8","key":"1103_CR188","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol. 2015;22(8):1184\u201391.","journal-title":"Eur J Neurol"},{"issue":"1-2","key":"1103_CR189","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jns.2006.05.014","volume":"248","author":"L Elmer","year":"2006","unstructured":"Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248(1-2):78\u201383.","journal-title":"J Neurol Sci"},{"issue":"10","key":"1103_CR190","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/mds.23738","volume":"26","author":"HA Hanagasi","year":"2011","unstructured":"Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, et al. The effects of rasagiline on cognitive deficits in Parkinson\u2019s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011;26(10):1851\u20138.","journal-title":"Mov Disord"},{"key":"1103_CR191","doi-asserted-by":"crossref","first-page":"e12106","DOI":"10.1002\/trc2.12106","volume":"7","author":"DC Matthews","year":"2021","unstructured":"Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, et al. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer\u2019s dementia. Alzheimers Dement. 2021;7:e12106.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1103_CR192","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1046\/j.1471-4159.2002.01047.x","volume":"82","author":"Y Akao","year":"2002","unstructured":"Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002a Aug;82(4):913\u201323.","journal-title":"J Neurochem"},{"issue":"12","key":"1103_CR193","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1096\/fj.04-1916fje","volume":"18","author":"O Weinreb","year":"2004","unstructured":"Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18(12):1471\u20133.","journal-title":"FASEB J"},{"issue":"1","key":"1103_CR194","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nbd.2006.07.020","volume":"25","author":"Y Sagi","year":"2007","unstructured":"Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis. 2007;25(1):35\u201344.","journal-title":"Neurobiol Dis"},{"key":"1103_CR195","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1742-2094-9-82","volume":"9","author":"R Gordon","year":"2012","unstructured":"Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A. Proteolytic activation of proapoptotic kinase protein kinase C\u03b4 by tumor necrosis factor \u03b1 death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation. 2012;9:82.","journal-title":"J Neuroinflammation"},{"issue":"20","key":"1103_CR196","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1111\/bph.14471","volume":"175","author":"IA Clark","year":"2018","unstructured":"Clark IA, Vissel B. Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, \u03b1-synuclein, amyloid-\u03b2 and insulin resistance in neurodegenerative diseases. Br J Pharmacol. 2018;175(20):3859\u201375.","journal-title":"Br J Pharmacol"},{"key":"1103_CR197","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nbd.2018.02.016","volume":"114","author":"Y Qi","year":"2018","unstructured":"Qi Y, Klyubin I, Cuello AC, Rowan MJ. NLRP3-dependent synaptic plasticity deficit in an Alzheimer\u2019s disease amyloidosis model in vivo. Neurobiol Dis. 2018;114:24\u201330.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1103_CR198","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbrc.2016.11.163","volume":"482","author":"DH Ho","year":"2017","unstructured":"Ho DH, Seol W, Eun JH, Son IH. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor \u03b1-mediated neurotoxicity. Biochem Biophys Res Commun. 2017;482(4):1088\u201394.","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"1103_CR199","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","volume":"84","author":"J Butchart","year":"2015","unstructured":"Butchart J, Brook L, Hopkins V, Teeling J, P\u00fcntener U, Culliford D, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161\u20138.","journal-title":"Neurology"},{"key":"1103_CR200","doi-asserted-by":"crossref","unstructured":"Camargo CHF, Justus FF, Retzlaff G, Blood MRY, Schafranski MD. Action of anti-TNF-\u03b1 drugs on the progression of Alzheimer\u2019s disease: A case report. Dement Neuropsychol. 2015;9:196\u2013200.","DOI":"10.1590\/1980-57642015DN92000015"},{"key":"1103_CR201","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1742-2094-5-2","volume":"5","author":"E Tobinick","year":"2008","unstructured":"Tobinick E, Gross H. Rapid cognitive improvement in Alzheimer\u2019s disease following perispinal etanercept administration. J Neuroinflammation. 2008;5:2.","journal-title":"J Neuroinflammation"},{"key":"1103_CR202","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fnins.2018.00626","volume":"12","author":"LM Butkovich","year":"2018","unstructured":"Butkovich LM, Houser MC, Tansey MG. \u03b1-Synuclein and noradrenergic modulation of immune cells in Parkinson\u2019s disease pathogenesis. Front Neurosci. 2018;12:626.","journal-title":"Front Neurosci"},{"key":"1103_CR203","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.lfs.2019.03.043","volume":"224","author":"FJ Cipr\u00e9s-Flores","year":"2019","unstructured":"Cipr\u00e9s-Flores FJ, Segura-Uribe JJ, Orozco-Su\u00e1rez S, Guerra-Araiza C, Guevara-Salazar JA, Castillo-Garc\u00eda EL, et al. Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampus. Life Sci. 2019;224:128\u201337.","journal-title":"Life Sci"},{"issue":"1","key":"1103_CR204","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.1038\/s41598-019-44803-1","volume":"9","author":"EJR Fletcher","year":"2019","unstructured":"Fletcher EJR, Jamieson AD, Williams G, Doherty P, Duty S. Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. Sci Rep. 2019;9(1):8336.","journal-title":"Sci Rep"},{"issue":"10","key":"1103_CR205","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3109\/02770903.2010.513077","volume":"47","author":"A Bozek","year":"2010","unstructured":"Bozek A, Krajewska J, Jarzab J. The improvement of cognitive functions in patients with bronchial asthma after therapy. J Asthma. 2010;47(10):1148\u201352.","journal-title":"J Asthma"},{"issue":"4","key":"1103_CR206","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00002826-200307000-00011","volume":"26","author":"EY Uc","year":"2003","unstructured":"Uc EY, Lambert CP, Harik SI, Rodnitzky RL, Evans WJ. Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease. Clin Neuropharmacol. 2003;26(4):207\u201312.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"1103_CR207","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1212\/WNL.44.8.1511","volume":"44","author":"GM Alexander","year":"1994","unstructured":"Alexander GM, Schwartzman RJ, Nukes TA, Grothusen JR, Hooker MD. Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson\u2019s disease. Neurology. 1994;44(8):1511\u20133.","journal-title":"Neurology"},{"issue":"8797","key":"1103_CR208","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/0140-6736(92)90313-R","volume":"339","author":"R Hishida","year":"1992","unstructured":"Hishida R, Kurahashi K, Narita S, Baba T, Matsunaga M. \u201cWearing-off\u201d and beta 2-adrenoceptor agonist in Parkinson\u2019s disease. Lancet. 1992;339(8797):870.","journal-title":"Lancet"},{"issue":"11","key":"1103_CR209","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40261-019-00830-4","volume":"39","author":"MS Cepeda","year":"2019","unstructured":"Cepeda MS, Kern DM, Seabrook GR, Lovestone S. Comprehensive real-world assessment of marketed medications to guide Parkinson\u2019s drug discovery. Clin Drug Investig. 2019;39(11):1067\u201375.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"1103_CR210","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.108","volume":"33","author":"N Gronich","year":"2018","unstructured":"Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W. \u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease. Mov Disord. 2018;33(9):1465\u201371.","journal-title":"Mov Disord"},{"issue":"5","key":"1103_CR211","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles Nielsen","year":"2018","unstructured":"Searles Nielsen S, Gross A, Camacho\u2010Soto A, Willis AW, Racette BA. \u03b22-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84(5):683\u201393.","journal-title":"Ann Neurol"},{"issue":"6354","key":"1103_CR212","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bj\u00f8rnevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357(6354):891\u20138.","journal-title":"Science"},{"key":"1103_CR213","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.2147\/DMSO.S229802","volume":"12","author":"S Pearson","year":"2019","unstructured":"Pearson S, Kietsiriroje N, Ajjan RA. Oral semaglutide in the management of type 2 diabetes: a report on the evidence to date. Diabetes Metab Syndr Obes. 2019;12:2515\u201329.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1103_CR214","unstructured":"ANZCTR \u2013 Registration. Available from: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=375958&showOriginal=true&isReview=true. Cited 2022 Jan 31."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01103-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01103-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01103-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T17:03:39Z","timestamp":1701363819000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01103-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":214,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01103-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JOB has acted as a consultant for TauRx, Eisai, Novo Nordisk, Biogen and GE Healthcare and received grant support from Avid\/ Lilly, MSD and Alliance Medical. J-PT has acted as a consultant for Sosei Heptares, Kyoma-Kirin and received speaker fees from GE Healthcare.FBPS has acted as a consultant for BiogenAbbVie and received speaker Lundbeck. DG has received grant funding from Parkinson\u2019s UK, honoraria from BIAL Pharma, AbbVie, Britannia Pharmaceuticals and consultancy fees from Roche and Biogen; FB is or was the national coordinator for France of clinical trials on DLB (Headway-DLB, Axovant; Delphia, Eisai) and AD (Graduate and PostGraduate, Roche).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}